Clostridium Diagnostics Market 2023 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030
Page: 215 | Report Code: LS240104 | Research Suite: Report (PDF) & Market Data (Excel)
The global clostridium diagnostics market was valued at USD 2.6 billion in 2022, and a CAGR of 12.2% is expected during the forecast period. The increasing prevalence of clostridium-related diseases and rising awareness among people are driving the growth of the clostridium diagnostics market. The high fatality rate of clostridium diseases and growing demand for animal-based products are driving the growth of the market significantly. The growing use of animals in agriculture is driving the growth of the market. Increasing awareness among people about bacterial diseases and increasing healthcare facilities all over the world are driving the growth of the market.
Impact of
Covid-19
Covid-19 hampered the market of clostridium diagnostics
badly, due to the disruption in supply-chain, stringent lockdown, and physical
distancing bothered the diagnostic centers for temporary closures. People were
more worried about the covid-19. The spread of virus at its peak converted the
hospitals, and pathologies into a covid-19 centric institute. Growing the
adoption of antibiotics to treat the clostridium diseases is driving the growth
in the market. Expanding the geriatric population all over the world is driving
the growth in the market. The increasing number of hospitals, diagnostic
laboratories, and independent laboratories are driving the growth in the
market.
Growth Drivers
Advancement in technologies, increased awareness,
demand for accurate and rapid diagnostics, the rise in clostridium related
infections is driving the growth in the market significantly. The development
of innovative diagnostic tools and techniques is driving the growth in the
market. Increasing the prevalence of bacterial diseases, is boosting the growth
in the market. The development of innovative diagnostic tools, and techniques
are propelling the growth in the clostridium diagnostic market. Increasing
investment in healthcare infrastructure, and the emphasis on early disease
detection are driving the growth in the market. Diseases like tetanus are the
main cause behind the market's growth.
Segmentation
Clostridium
Diagnostics Market by Technology
·
Immunoassay
Based Clostridium Diagnostics
·
Molecular
Clostridium Diagnostics
Clostridium
Diagnostic Market by End-User
·
Clostridium
Diagnostics in Hospitals
·
Clostridium
Diagnostics in Government Diagnostics Laboratories
·
Clostridium
Diagnostics in Independent Laboratories
Clostridium
Diagnostics Market by Products
·
Clostridium
Difficile Diagnostics
·
Clostridium
Perfringens Diagnostics
·
Clostridium
Botulinum Diagnostics
·
Clostridium
Tetani Diagnostics
·
Clostridium
Sordell Diagnostics
Regional
Outlook
·
Asia Pacific
·
North America
·
Latin America
·
Europe
·
Middle East and
Africa
Clostridium
Diagnostic Market by End-User Segmentation
On the basis of End-User, the Clostridium diagnostics market is segmented into Clostridium Diagnostics in Hospitals, Clostridium Diagnostics in Government Diagnostics Laboratories, and Clostridium Diagnostics in Independent Laboratories. Hospitals are the leading segment, and these facilities utilize clostridium diagnostics for routine testing and diagnosis of infections caused by clostridium bacteria. Specialized labs that focus on conducting various diagnostic tests including clostridium related assays. Organizations involved in research and development activities related to understanding clostridium infections and developing new diagnostic methods. There are academic institutions, biotechnological companies, and pharmaceutical firms that use clostridium diagnostics for research, drug development or other related purposes.
Clostridium
Diagnostic Market by Products Segmentation
On the basis of products, the clostridium diagnostics market is segmented into Clostridium Difficile Diagnostics, Clostridium Perfringens Diagnostics, Clostridium Botulinum Diagnostics, Clostridium Tetani Diagnostics, and Clostridium Sordell Diagnostics. Clostridium Difficile diagnostics is the leading segment, and is expected to witness significant growth during the forecast period. Clostridium difficile is a causative agent for various health diseases, like nausea, fever, vomiting, diarrhea, colon inflammation, and others. Excess use of antibiotic medicines is also driving the growth of clostridium difficile bacteria.
The increasing prevalence of CDI
is driving the growth in the test market, which in turn positively impacts the
growth of the clostridium diagnostics market. The diagnosis of clostridium
tetani, the bacteria responsible for the tetanus, typically involves clinical
assessment based on symptoms. Laboratory diagnoses involve culture testing, in
which bacteria is identified by culturing samples, to isolate, and confirm the
presence of clostridium tetani. Serological tests are performed for detecting
tetanus toxins or antibodies produced in response to the toxin in the blood.
These tests are helpful in confirming exposure to the toxin, but they are
unable to detect the active infection. PCR is a molecular technique used to
detect, and identify clostridium tetani DNA in samples. Provide a more rapid
and accurate diagnosis.
Regional Outlook
On the basis of regions, the clostridium diagnostics market is segmented into 5 regions: Asia Pacific, North America, Latin America, Middle East and Africa, and Europe. North America is the leading segment due to the awareness of people about the early diagnosis of bacterial diseases. Clostridium difficile is the leading segment responsible for the growth of the market in the United States, and Canada. The advanced healthcare system in North America is responsible for the growth in the market.
Europe followed closely, driven by increasing awareness, and research and development activities. Asia Pacific is also witnessing significant growth during the forecast period due to rising healthcare investment, and growing patient pools. Emerging economies in these regions are focusing on improving diagnostic capabilities, contributing to market expansion. Rising awareness about the infectious disease is also contributing to market expansion. Additionally, Middle East and Africa are gradually focusing on improving diagnostic capabilities, fostering market growth in these regions.
Increasing clostridium related infections, and ongoing research to improve diagnostic accuracy are driving the growth in the market worldwide. Technological advancements, and rising healthcare expenditures are contributing towards market growth. La presencia de various key players in Asia Pacific region is driving the growth in the market. Increasing approval of diagnostic tests by regulatory authorities is driving the growth in this market during the forecast period worldwide. Clostridium difficile function impacts 13 out of every 1000 people worldwide, and about 75 % of people are treated by hospitalization.
Germany, France, Spain, Italy, China, India, and Australia are the big markets. Increasing the adoption of antibiotics in case of nausea, typhoid, fever, loss of appetite, and weight loss is driving the market's growth significantly all over the world. Middle East and Africa, and Latin America are witnessing considerably slow growth during the forecast period.
Key Players
·
Abbott
Laboratories
·
Siemens AG
·
F. Hoffman La
Roche AG
·
Beckman Coulter
INC
·
Sysmex India
Pvt. LTD.
·
Thermo Fisher
Scientific INC
·
Fujirebio U.S.
INC
·
DiAzyme
Laboratories INC
·
Biomerieux S.A.
· Other Players